SpinChip Diagnostics to be Acquired by bioMérieux13.1.2025 07:03:51 CET | SpinChip Diagnostics ASA | Pressemelding
Transaction Valuation: SpinChip valued at NOK 1,624 million (EUR 138 million), making it one of the largest MedTech transactions in Norway. Menu Development: bioMérieux will accelerate the menu build-up of SpinChip’s Point of Care diagnostics platform. Strategic Growth: bioMérieux strengthens its position in the Point of Care market. Oslo, Norway, 13 January 2025 — SpinChip Diagnostics ASA (“SpinChip”), an innovative diagnostics company developing next-generation Point of Care platforms for in vitro diagnostics, announces its agreement to be acquired by bioMérieux, a global leader in in vitro diagnostics. Under the agreement, bioMérieux will acquire 100% ownership of SpinChip for a Total Enterprise Value of NOK 1,624 million. Morten Jurs, Chief Executive Officer of SpinChip, stated: “The dedication of the SpinChip team over the past decade has been exceptional. Their relentless efforts have led to the development of a groundbreaking diagnostics platform that has the potential to signif